Malignant Pleural Effusion Market To Grow At 4.9% CAGR Through 2036, Driven By Rising Cancer Burden, Increasing Demand For Minimally Invasive Treatments, And Emerging Therapeutic Approaches Delveins

(MENAFN- GetNews) DelveInsight's latest report,“Malignant Pleural Effusion Market Insights, Epidemiology and Market Forecast – 2036,” provides a comprehensive analysis of the Malignant Pleural Effusion (MPE) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the Malignant Pleural Effusion market size across the 7MM was approximately USD 2 billion in 2025 and is projected to grow at a CAGR of 4.9% during 2026–2036.

(Albany, New York)- 10th Sep 2026 - DelveInsight's latest report,“Malignant Pleural Effusion Market Insights, Epidemiology and Market Forecast – 2036,” provides a comprehensive analysis of the Malignant Pleural Effusion (MPE) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the Malignant Pleural Effusion market size across the 7MM was approximately USD 2 billion in 2025 and is projected to grow at a CAGR of 4.9% during 2026–2036.

The Malignant Pleural Effusion treatment landscape is currently dominated by palliative and drainage-based interventions because of the absence of FDA-approved curative therapies. Increasing cancer incidence, an aging population, advances in diagnosis, demand for minimally invasive symptom-management procedures, and the development of novel targeted and immunotherapeutic approaches are expected to create new opportunities in the MPE market through 2036.

Key Takeaways from the Malignant Pleural Effusion Market

• The 7MM Malignant Pleural Effusion market size was approximately USD 2 billion in 2025 and is expected to grow at a 4.9% CAGR during 2026–2036.

• The United States accounted for more than USD 1 billion of the Malignant Pleural Effusion therapeutics market in 2025 and is expected to maintain its leading position.

• The 7MM recorded approximately 480,000 Malignant Pleural Effusion incident cases in 2025.

• The United States recorded approximately 180,000 MPE incident cases in 2025, the highest among the 7MM.

• In the United States, females accounted for approximately 100,000 incident cases, while males accounted for nearly 70,000 cases in 2025.

• Across the EU4 and the UK, approximately 50,000 MPE cases were associated with breast cancer and more than 25,000 cases were associated with lymphoma in 2025.

• Japan recorded nearly 50,000 symptomatic MPE cases and approximately 12,000 asymptomatic cases in 2025.

• Current MPE management predominantly relies on thoracentesis, pleurodesis, indwelling pleural catheters, tube thoracostomy, and other drainage procedures for symptom relief.

• The emerging pipeline includes PTS500, M701, and RSO-021, representing different therapeutic mechanisms and approaches to MPE management.

• Key companies involved in the MPE pipeline include Gongwing Biopharm, Wuhan YZY Biopharma, RS Oncology, and Genelux Corporation.

Keen to know more about the Malignant Pleural Effusion Market Report?

Key Factors Driving the Malignant Pleural Effusion Market

Rising Prevalence of Cancer-associated Conditions

The increasing incidence of cancers such as lung cancer, breast cancer, and lymphoma is a major driver of the MPE market because malignant pleural effusion commonly occurs as a complication of advanced malignancies. Rising cancer incidence and improved survival are contributing to a larger population at risk of developing MPE.

Growing Geriatric Population

The aging population is more susceptible to cancer and associated complications, including malignant pleural effusion. The expansion of the geriatric population is therefore expected to contribute to the overall MPE patient pool and increase demand for symptom-management and supportive treatment approaches.

Advancements in Diagnostic Techniques

Improvements in chest ultrasonography, computed tomography, PET-CT, pleural biopsy, and medical thoracoscopy are supporting more accurate detection, characterization, staging, and management of MPE. Improved diagnostic capabilities can facilitate earlier identification of malignant pleural disease and guide treatment decisions.

Increasing Demand for Minimally Invasive Treatments

The increasing use of minimally invasive approaches such as thoracentesis, indwelling pleural catheters, and pleurodesis is an important factor shaping the current treatment landscape. These interventions are primarily aimed at reducing pleural fluid accumulation, relieving dyspnea, and improving patient comfort and quality of life.

Development of Novel Therapeutic Approaches

The absence of approved curative therapies represents a substantial unmet need and is encouraging pharmaceutical innovation. Emerging candidates are exploring mechanisms including T-cell activation, peroxiredoxin III inhibition, and cell-death stimulation, potentially expanding the treatment landscape beyond conventional drainage-based management.

Competitive Landscape

The Malignant Pleural Effusion market remains an emerging therapeutic landscape, with current management primarily centered on palliative procedures rather than approved pharmaceutical therapies. Thoracentesis, pleurodesis, and indwelling pleural catheters remain important components of standard care, while emerging pharmaceutical candidates seek to address the limitations of temporary symptom relief and frequent recurrence.

Among pipeline therapies, PTS500 from Gongwing Biopharm is a Phase II candidate being investigated for MPE, with a proposed cell-death-stimulating mechanism and intratumoral administration. M701 from Wuhan YZY Biopharma is a Phase II bispecific antibody targeting EpCAM and CD3, designed to activate T cells against tumor cells within the pleural cavity. RSO-021 from RS Oncology is being evaluated in Phase I/II development as a peroxiredoxin III inhibitor administered through pleural infusion.

The competitive pipeline is expected to remain focused on developing therapies that can reduce recurrent fluid accumulation, improve symptom control, and potentially provide more durable disease management.

Recent Developments in the Malignant Pleural Effusion Market

• February 2026: Wuhan YZY Biopharma received FDA approval for its IND application for M701, a bispecific antibody being developed for MPE in patients with advanced lung and breast cancers.

• June 2024: RS Oncology reported positive data from the Phase I trial of RSO-021.

• March 2024: RS Oncology reported two abstracts containing preclinical and translational data supporting RSO-021, which were accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research.

• ESMO 2024: Intrathoracic administration of M701 demonstrated promising findings, including a 61.5% pleurodesis success rate and puncture-free survival of 237 days in the reported analysis.

What is Malignant Pleural Effusion?

Malignant Pleural Effusion is a condition characterized by the accumulation of fluid containing malignant cells in the pleural space between the chest wall and lungs. It is a serious complication of advanced cancer and is associated with substantial morbidity, impaired quality of life, and poor prognosis.

MPE is most commonly associated with lung cancer, followed by breast cancer, lymphoma, gynecological cancers, and malignant mesothelioma. Diagnosis can involve chest ultrasonography, CT, PET-CT, pleural biopsy, and cytological examination. Image-guided pleural biopsy and medical thoracoscopy can provide important diagnostic information when required.

Current Treatment Landscape

The current treatment approach for MPE primarily focuses on palliation of symptoms and improvement of quality of life. Therapeutic thoracentesis is commonly used to relieve dyspnea and assess lung re-expansion and recurrence.

Pleurodesis aims to eliminate the pleural space and prevent recurrent fluid accumulation. Talc is an important sclerosant, and talc poudrage during thoracoscopy may provide effective recurrence prevention. Tunneled and indwelling pleural catheters provide another option, allowing continued drainage and, in some cases, home management.

Other approaches include systemic cancer therapy, anti-angiogenic agents, immunotherapy, thoracoperitoneal shunts, and supportive care. However, recurrent effusion, procedure-related complications, pain, and the lack of curative pharmacological treatments continue to represent major unmet needs.

Malignant Pleural Effusion Epidemiology Segmentation

The Malignant Pleural Effusion epidemiology analysis covers:

• Total Malignant Pleural Effusion Incident Cases

• Tumor Type-specific Incident Cases

• Gender-specific Incident Cases

• Symptom-specific Incident Cases

According to DelveInsight, approximately 480,000 MPE incident cases were reported across the 7MM in 2025. In the United States, approximately 180,000 incident cases were reported, including nearly 100,000 female cases and 70,000 male cases. Across EU4 and the UK, approximately 50,000 breast cancer-associated cases and more than 25,000 lymphoma-associated cases were recorded in 2025.

Scope of the Malignant Pleural Effusion Market Report

• Study Period: 2022–2036

• Historical Year: 2022–2025

• Forecast Period: 2026–2036

• Base Year: 2025

• Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and Japan

• Market CAGR: 4.9% during 2026–2036

• Market Segmentation: Region/Geographies and Drugs/Therapies

• Epidemiology Segmentation: Malignant Pleural Effusion incident cases, tumor type-specific incident cases, gender-specific incident cases, and symptom-specific incident cases

• Key Companies Covered: Gongwing Biopharm, Wuhan YZY Biopharma, RS Oncology, Genelux Corporation, and others

• Key Emerging Therapies Covered: PTS500, M701, RSO-021, and others

• Market Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs

• Clinical Development Assessment: Clinical development of emerging therapies, mechanisms of action, clinical trial data, regulatory milestones, patents, collaborations, strategic partnerships, upcoming catalysts, advantages, limitations, and recent developments

• Market Assessment: Historical and forecasted market size, market share by therapies, treatment practices, therapy uptake, patient burden, competitive landscape, pricing trends, and market opportunities across the 7MM

• Report Insights: MPE patient population forecast, therapeutics market size, pipeline analysis, market size and trends, and current and forecasted market opportunity

• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year market forecast, regional outlook across North America, Europe, and Asia-Pacific, patient burden trends, treatment addressable market, competitive landscape, major company insights, price trends and analogue assessment, drug adoption/uptake, and peak patient share analysis.

To know more about the clinical trials, emerging therapies, market landscape, and therapeutic assessment of Malignant Pleural Effusion:View the Malignant Pleural Effusion Market Report

Table of Contents

Key Insights

Report Introduction

Executive Summary

Key Events

Epidemiology and Market Methodology

Malignant Pleural Effusion Market Overview

Disease Background and Overview

Causes

Signs and Symptoms

Diagnosis

Current Treatment Landscape

Unmet Needs

Epidemiology

Epidemiology Forecast

Emerging Therapies

Drug Analysis and Competitive Landscape

Market Forecast

Drug Uptake

Market Access and Reimbursement

Pricing and Cost Analysis

KOL Views

SWOT and Conjoint Analysis

Market Drivers and Barriers

Competitive Landscape

Appendix

Methodology

About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

MENAFN10092026003238003268ID1111650011